We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $1.47B | 27.16% |
19,991,024
| – | – |
|
2
Viatris
VTRS
$20.1B
| $215M | 3.97% |
19,863,484
-1
| -0% | -$10 |
|
|
CPRX
3
DELISTED
Catalyst Pharmaceutical
CPRX
| $149M | 2.76% |
8,888,901
+696,901
| +9% | +$9.53M |
|
4
Centene
CNC
$32.8B
| $148M | 2.73% |
1,991,799
+1,799
| +0.1% | +$130K |
|
|
5
Neurocrine Biosciences
NBIX
$17.2B
| $118M | 2.18% |
896,719
-312,995
| -26% | -$36M |
|
|
6
Oscar Health
OSCR
$8.77B
| $103M | 1.9% |
+11,246,820
| New | +$77.6M |
|
|
ACH
7
Accendra Health
ACH
$266M
| $101M | 1.86% |
5,229,779
-1,205,221
| -19% | -$21.8M |
|
8
AdaptHealth
AHCO
$1.49B
| $99.2M | 1.83% |
13,607,940
| – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $94.3M | 1.74% |
2,584,376
+1,004,802
| +64% | +$26.2M |
|
10
IDEAYA Biosciences
IDYA
$3.47B
| $93.6M | 1.73% |
2,630,292
+361,664
| +16% | +$10.8M |
|
|
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $93.4M | 1.72% |
5,788,024
-1,109,582
| -16% | -$14.2M |
|
|
12
Revolution Medicines
RVMD
$39.6B
| $88.6M | 1.64% |
3,090,073
+1,338,577
| +76% | +$32.2M |
|
13
Brookdale Senior Living
BKD
$3.58B
| $86.1M | 1.59% |
14,793,264
+2,113,613
| +17% | +$9.92M |
|
|
MRUS
14
DELISTED
Merus
MRUS
| $83M | 1.53% |
3,019,901
-857,037
| -22% | -$20M |
|
15
Larimar Therapeutics
LRMR
$384M
| $77.1M | 1.42% |
16,941,357
| – | – |
|
16
Kura Oncology
KURA
$964M
| $76.4M | 1.41% |
5,312,733
+938,689
| +21% | +$9.23M |
|
17
Surgery Partners
SGRY
$2.09B
| $67.4M | 1.24% |
2,105,509
+645,509
| +44% | +$18.7M |
|
|
HLVX
18
DELISTED
HilleVax
HLVX
| $64.3M | 1.19% |
4,004,231
| – | – |
|
|
RYZB
19
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $62.6M | 1.16% |
1,006,126
-153,000
| -13% | -$3.8M |
|
|
FUSN
20
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $61.5M | 1.14% |
6,401,000
+3,578,000
| +127% | +$17.4M |
|
21
ARS Pharmaceuticals
SPRY
$695M
| $60.7M | 1.12% |
11,077,927
| – | – |
|
|
22
Baxter International
BAX
$11.7B
| $52.5M | 0.97% |
+1,358,686
| New | +$48.1M |
|
|
EHAB
23
DELISTED
Enhabit
EHAB
| $51.7M | 0.96% |
4,997,746
| – | – |
|
24
Integra LifeSciences
IART
$1.5B
| $49.2M | 0.91% |
1,128,999
+2,172
| +0.2% | +$85.5K |
|
25
Bio-Rad Laboratories Class A
BIO
$8.15B
| $48.9M | 0.9% |
151,575
-22,372
| -13% | -$7.01M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.